29 Jun 2021Ended

Generating CAR or TCR T Cells to Clinical Scale in a quick GMP-compatible Manufacturing Workflow using nS/MARt DNA Vectors with MaxCyte Flow Electroporation


Estimated Turnout

upto 100
Based on previous editions


Jun 2021


Not Available
Claim event to edit details

The compelling need to provide adoptive cell therapy (ACT) to an increasing number of oncology patients within a meaningful therapeutic window makes .. Read more the development of an efficient, fast, versatile, and safe genetic tool for creating recombinant T cells indispensable. Despite the extraordinary efficacy shown by recombinant T cells expressing Chimeric Antigen Receptors (CARs) in numerous clinical trials, significant challenges remain, ranging from a long lead time, and expensive manufacturing to complicated vector-engineering, optimized gene expression and delivery, and reduced vector-mediated toxicities The DNA Vector Lab at the DKFZ has developed Nano-S/MARt (nS/MARt), a novel DNA Vector platform that combines prolonged CAR-TCR expression with minimal disruption of T cell activity.

  • Share your Experience
  • Organizer
Logo Follow Company


USA1 Total Event

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results